BENGALURU (Reuters) - Indian biopharma company Biocon sold a 9.96% stake in its unit and contract research firm Syngene International through open market sale, it said in an exchange filing on Wednesday.
With the sale, the total promoter stake of Biocon in Syngene stands at 54.6%, the exchange filing showed.
Biocon did not reveal the price at which the stake was sold.
Officials at Syngene and Biocon did not immediately respond to a Reuters query seeking the reason for the stake sale and the price at which the sale was executed.
Biocon was selling the stake in Syngene to fund the acquisition of Viatris Inc's biosimilars business that it announced last year, CNBC TV-18 reported on Tuesday.
The selling price would be in the range of 560 rupees and 562.30 rupees per share, the report said.
Biocon Biologics had in February 2022 said it would buy the U.S. drug maker's biosimilars business in a deal valued at $3.34 billion.
Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing.
Biocon's shares closed up 2%, while those of Syngene added 0.74% on Wednesday.
(Reporting by Nallur Sethuraman in Bengaluru; Editing by Dhanya Ann Thoppil)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app